Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum Theodore GREINER, Neil R. BURCH, Robert EDELBERG AMA, Archives of Neurology & Psychiatry, 1958, 79, (2), 208-210. doi:10.1001/archneurpsyc.1958.02340020088016 Abstract Despite 14 years of investigation, as intensive as accorded any biologically active chemical, a gap remains in the systematic description of human response to lysergic acid diethylamide (LSD-25). The dramatic schizophrenic-like symptoms after doses of 40 μg to 100 μg have drawn the main interest. The threshold for activity is placed at 20 μg by general consensus, while perfunctory administration of smaller doses has left their effect uncertain. Accompanying those pharmacologic demonstrations has been [...]
Lire la suiteFunctional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis Robin L. Carhart-Harris, Robert Leech, David Erritzoe, Tim M. Williams, James M. Stone, John Evans, David J. Sharp, Amanda Feilding, Richard G. Wise, and David J. Nutt Schizophrenia Bulletin, 2012, Volume 39, Issue 6, November 2013, Pages 1343–1351 doi : 10.1093/schbul/sbs117 Psilocybin is a classic psychedelic and a candidate drug model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamo-cortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on [...]
Lire la suiteFrom experimental psychosis to resolving traumatic pasts - Psychedelic Research in Communist Czechoslovakia, 1954‑1974 De la psychose expérimentale à la guérison des traumatismes du passé : la recherche psychédélique en Tchécoslovaquie communiste, 1954‑1974 Sarah Marks Cahiers du monde russe, 2015, 56, 1, 53-75. DOI: 10.4000/monderusse.8165 The mid‑twentieth century saw an abundance of new theories of human behaviour and mental disorder, many of which were inspired by new developments in broader scientific fields, from cybernetics and genetics, to pharmaceuticals and new technologies of psychological testing1. There is a developing historical literature on the development of psychiatry in Western Europe and North America, yet we know little [...]
Lire la suiteNeurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG Euphrosyne Gouzoulis-Mayfrank, Mathias Schreckenberger, Osama Sabri, Christoph Arning, Bernhard Thelen, Manfred Spitzer, Ph.D., Karl-Artur Kovar, Leopold Hermle, Udalrich Büll, and Henning Sass. NEUROPSYCHOPHARMACOLOGY, 1999–VOL 20, NO 6, 565-581. PII S0893-133X(98)00089-X The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4- methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg) and the drugs’ interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n 5 8). Subjects underwent two scans (control: [...]
Lire la suiteLSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]
Lire la suiteLSD : le retour de l’enfant terrible par Didier ACIER pour laviedesidees.fr, https://laviedesidees.fr/LSD-le-retour-de-l-enfant-terrible.html 6 mars 2015 Indissociable du mouvement hippie, l’usage récréatif de LSD-25 a donné lieu à l’interdiction précoce de ce médicament. Le potentiel psychothérapeutique de l’acide lysergique diéthylamide est pourtant bien établi, notamment en matière de soins palliatifs, et l’on peut souhaiter que l’exploration scientifique et médicale de ce produit se développe à l’avenir. Genèse d’un médicament Printemps 1943 en Suisse, à Bâle. Albert Hoffmann, chimiste de son état, synthétise pour la compagnie Sandoz, des alcaloïdes, à partir de l’ergot de seigle. Sa recherche vise à développer de nouveaux médicaments. Alors qu’il travaille sur l’acide [...]
Lire la suite